Futura has today announced FY results broadly in line with expectations, and provided a comprehensive update on the status of its development pipeline and product portfolio. Significant news includes a first commercial order for CSD500 (erectogenic condom) from an existing partner and the appointment of advisers to manage the out-licensing process for TPR100 and TIB200 (topical pain relief), for which regulatory dossiers will be submitted by year-end. We note that the European market for OTC top ....
15 Mar 2016
FY results in line, first CSD500 order, pain deal sought, EroxonTM on track N+1 Singer view
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY results in line, first CSD500 order, pain deal sought, EroxonTM on track N+1 Singer view
Futura Medical plc (FUM:LON) | 35.7 -0.1 (-0.6%) | Mkt Cap: 107.7m
- Published:
15 Mar 2016 -
Author:
Dr Jens Lindqvist -
Pages:
4
Futura has today announced FY results broadly in line with expectations, and provided a comprehensive update on the status of its development pipeline and product portfolio. Significant news includes a first commercial order for CSD500 (erectogenic condom) from an existing partner and the appointment of advisers to manage the out-licensing process for TPR100 and TIB200 (topical pain relief), for which regulatory dossiers will be submitted by year-end. We note that the European market for OTC top ....